Literature DB >> 3144206

Weekly cuirass ventilation improves blood gases and inspiratory muscle strength in patients with chronic air-flow limitation and hypercarbia.

M Gutiérrez1, T Beroíza, G Contreras, O Díaz, E Cruz, R Moreno, C Lisboa.   

Abstract

We studied the effects of an 8-h, once-a-week schedule of cuirass ventilation (CV) in 5 patients with advanced chronic air-flow limitation and chronic hypercarbia (PaCO2, 58.6 +/- 10.1 mm Hg; mean +/- SD). Repeated measurements of arterial blood gases, maximal inspiratory mouth pressure (P1max), 12-min walking distance, and respiratory cycle were performed during a 1-month run-in period. Quality of life and transdiaphragmatic pressure were measured once. All patients completed the planned 4-month study. Four of them were ventilated for longer periods because CV could not be discontinued at the end of the study. PaCO2 showed a significant fall starting during the first month; PaO2 significantly increased from the second month, whereas P1max significantly rose from the third month on. Maximal transdiaphragmatic pressure increased in the 2 patients with abnormal baseline values. The fall in PaCO2 was associated with an increase in tidal volume because of a longer inspiratory time. Significant improvements in quality of life and in the 12-min walking distance were observed. We conclude that weekly CV improves blood gases, inspiratory muscle strength, and clinical conditions of patients with chronic air-flow limitation and chronic hypercarbia, probably because of correction of chronic inspiratory muscle fatigue.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144206     DOI: 10.1164/ajrccm/138.3.617

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Induction of sleep apnoea with negative pressure ventilation in patients with chronic obstructive lung disease.

Authors:  R D Levy; M G Cosio; L Gibbons; P T Macklem; J G Martin
Journal:  Thorax       Date:  1992-08       Impact factor: 9.139

Review 2.  Mechanical exsufflation, noninvasive ventilation, and new strategies for pulmonary rehabilitation and sleep disordered breathing.

Authors:  J R Bach
Journal:  Bull N Y Acad Med       Date:  1992 Mar-Apr

3.  Domiciliary ventilation in chronic obstructive lung disease.

Authors:  P M Calverley
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

Review 4.  Assessing quality of life in chronic non-specific lung disease--a review of empirical studies published between 1980 and 1994.

Authors:  A R Maillé; A A Kaptein; J C de Haes; W T Everaerd
Journal:  Qual Life Res       Date:  1996-04       Impact factor: 4.147

5.  Effect of negative pressure ventilation on arterial blood gas pressures and inspiratory muscle strength during an exacerbation of chronic obstructive lung disease.

Authors:  J M Montserrat; J A Martos; A Alarcon; R Celis; V Plaza; C Picado
Journal:  Thorax       Date:  1991-01       Impact factor: 9.139

6.  Pulmonary rehabilitation coupled with negative pressure ventilation decreases decline in lung function, hospitalizations, and medical cost in COPD: A 5-year study.

Authors:  Hung-Yu Huang; Pai-Chien Chou; Wen-Ching Joa; Li-Fei Chen; Te-Fang Sheng; Horng-Chyuan Lin; Lan-Yan Yang; Yu-Bin Pan; Fu-Tsai Chung; Chun-Hua Wang; Han-Pin Kuo
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

7.  Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV.

Authors:  Annabel H Nickol; Nicholas Hart; Nicholas S Hopkinson; Carl-Hugo Hamnegård; John Moxham; Anita Simonds; Michael I Polkey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 8.  Noninvasive ventilation in stable hypercapnic COPD: what is the evidence?

Authors:  Marieke L Duiverman
Journal:  ERJ Open Res       Date:  2018-04-09

9.  A pilot study of short-term hemodynamic effects of negative pressure ventilation in chronic obstructive pulmonary disease assessed using electrical cardiometry.

Authors:  Ke-Yun Chao; Yasser Nassef
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-03-17       Impact factor: 1.468

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.